Background and Aims: Uterine sarcomas represent 8% of uterine body malignant tumours, about one-third of which are considered leiomyosarcoma. Uterine leiomyosarcoma shows distant metastasis at an early stage, is resistant to chemo-and radiotherapy and displays poor prognosis. Although resection is reportedly effective against pulmonary metastasis, progression is often very fast and the opportunity of resection is frequently missed, and reports of resection cases are extremely few.
other nodular lesions were noted in the other lung lobes, and swelling of the mediastinal and hilar lymph nodes was not observed. On FDG-PET examination, SUVmax was 2.4 in the same lung nodule, and no accumulation was identified in other parts of the whole body. On suspicion of single lung metastasis from uterine sarcoma, thoracoscopic partial resection of the right upper lobe of the lung was performed. The postoperative course was good. Proliferation of spindle cells was found on pathological examination, similar to the histology of the previous uterine lesions, suggesting lung metastasis of leiomyosarcoma. Since surgery, follow-up observation has been carried out on an outpatient basis with no administration of anticancer agent, and no recurrence has been recognized as of 7 months postoperatively.
Conclusion:
We successfully performed a surgery for lung metastasis occurring after surgery for uterine leiomyosarcoma. Background and Aims: Aberrant glycosylation has been known to regulate cancer cell trafficking via promoting intravascular adhesion during metastasis. Clinicopathological studies have also shown a strong correlation between aberrant glycosylation and invasive/metastatic potentials of human cancers. However, the major glycosylation enzymes that drive lung cancer metastases and the signalling networks involved in the process remain incompletely understood.
Methods:
We identified fucosyltransferase 4 (FUT4) as a strong predictor of patient prognosis from two independent cohorts of patients with NSCLC (TCGA and NTUH). We analyzed functional roles of FUT4 through over-expression and knock-down studies using lung cancer cell lines in vitro. Metastatic and homing potentials of FUT4-overexpressed and/or knockdown cells were evaluated in vivo in immunodeficient mice. Genome-wide RNA-seq and MS-based immune-precipitation proteomics were performed to study molecular signalling networks.
Results: High expressions of FUT4 were associated with poor survivals in lung adenocarcinomas (P = 0.000681). FUT4-overexpressing lung cancer cells showed significantly increased migration, invasion, and adhesion abilities in vitro, as well as enhanced homing ability to the lungs in vivo. FUT4-overexpressing cells displayed typical characteristics of epithelial-to-mesenchymal transition (EMT) in a protein level-dependent manner. Lewis X and AAL antigens were significantly up-regulated in FUT4-overexpressing cells, which facilitated binding to E-and L-selections. Gene Set Enrichment Analyses of RNA-seq data highlighted metastasis-related signalling, especially EGF and TGF-β pathways. Molecularly, FUT4 enhanced EGFR/TGFBR signalling through glycosylation of multiple pathway proteins.
Conclusion: FUT4 promoted metastasis through enhancing mesenchymal phenotype mediated by glycosylated EGFR/TGFBR signalling, and through increasing binding affinity of cancer cells to selections. High levels of FUT4 in tumor tissues significantly correlated with poor prognosis in NSCLC patients. Our study not only provided new insights into the role of FUT4 on molecular signalling as a potential therapeutic target, but also identified FUT4 as a prognostic marker in NSCLC. The initial treatment effect of 43 pts (NIVO: 33 PEMB:9) was PD We classified this pts into two groups, HPD group and non-HPD group.
The definition of HPD was defined as a Response Evaluation Criteria in Solid Tumours (RECIST) progression at the first evaluation and a 2-fold or greater increase in tumor growth rate from baseline (before treatment with immunotherapy).
Results: 7 cases (16%) were classified into HPD group.
Median survival of HPD group was 175 days (54-618). Median survival of non-HPD group was 141 days (22-635). In the HPD group, the proportion of cases where the tumor growth rate in the prior treatment was 2 times or more was 3 out of 7 cases.
Conclusion:
Half of those classified into HPD group have a high rate of tumor growth in the prior treatment.
Both disease progression affected by immunotherapy and disease progression due to characteristics of the tumor itself. 
